What is HC Wainwright’s Forecast for Nkarta Q1 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Nkarta in a research note issued on Thursday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.80) EPS and FY2028 earnings at ($1.54) EPS.

Several other brokerages have also commented on NKTX. Stifel Nicolaus cut their price objective on Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Nkarta in a research note on Thursday. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $14.86.

Nkarta Stock Up 1.5 %

Nkarta stock opened at $2.00 on Monday. The business has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $2.82. Nkarta has a 52 week low of $1.31 and a 52 week high of $11.84. The stock has a market cap of $141.92 million, a price-to-earnings ratio of -1.06 and a beta of 0.90.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06.

Insiders Place Their Bets

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NKTX. Invesco Ltd. purchased a new stake in Nkarta during the 4th quarter valued at about $30,000. Sequoia Financial Advisors LLC bought a new stake in Nkarta in the fourth quarter valued at approximately $31,000. Erste Asset Management GmbH purchased a new stake in shares of Nkarta during the third quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Nkarta in the fourth quarter worth approximately $37,000. Finally, ProShare Advisors LLC purchased a new position in shares of Nkarta in the fourth quarter worth $45,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.